Background
Thymosin Beta-4 (Tβ4), also known by its synthetic fragment TB-500, is a 43-amino-acid peptide originally isolated from bovine thymus. It is the primary actin-sequestering protein in mammalian cells, regulating cell motility, proliferation, and differentiation. Beyond its structural role, Tβ4 promotes angiogenesis, wound healing, and cardiac protection.
TB-500 refers to a synthetic fragment or the full Tβ4 peptide used in research and off-label therapeutic contexts. This foundational review by Goldstein, Hannappel, and Kleinman synthesizes the biological evidence for Tβ4’s regenerative properties.
Methods
Narrative review of in vitro and animal studies examining Tβ4’s role in:
- Wound healing (corneal, skin, muscle)
- Cardiac repair post-MI
- Anti-inflammatory and angiogenic mechanisms
Key Findings
Wound healing:
- Significantly accelerated corneal wound closure in rabbit and mouse models (50% faster re-epithelialization)
- Reduced scar formation; promoted organized collagen deposition
- Topical Tβ4 applied to skin wounds produced faster healing vs. vehicle
Cardiac repair:
- Post-MI myocardial infarct: Tβ4 significantly reduced infarct size in rat models
- Increased coronary artery collateral vessel formation
- Promoted cardiomyocyte survival and proliferation from epicardial progenitor cells
Angiogenesis:
- Direct stimulation of endothelial cell migration via IQGAP1 and ILK pathways
- Enhanced VEGF-independent angiogenesis
Actin/anti-inflammatory mechanism:
- Sequesters G-actin, reducing pro-inflammatory actin secretion from damaged cells
- Downregulates NF-κB signaling in macrophages
Clinical Significance
Tβ4 has entered human clinical trials for chronic wound healing (RegaFlex trials) and was in Phase II development for acute MI. The wound healing and cardiac repair applications have the strongest biological support.
TB-500 (synthetic Tβ4 fragment) is widely used in athletic recovery and injury rehabilitation contexts, where its tissue-repair and anti-inflammatory properties are sought, though human RCT data for these applications remains absent.
Limitations
- Comprehensive human RCT data lacking; most evidence is preclinical
- Regulatory: TB-500 is not FDA-approved for any indication
- Dose-response in humans poorly characterized
- Manufacturing and purity standards variable for non-pharmaceutical grade product